tirzepatide la jolla FDA approves weight-loss drug Zepbound to treat sleep apnea – San Diego Union-Tribune America's New No. 1 Beach

Food and Drug Administration (FDA) officially approved Zepbound (tirzepatide) injection, under the brand name Mounjaro for chronic weight management in 2023

But if you are using the multi-dose vial format , this timeline becomes very important

Some insurance companies and Medicare may cover part of the cost

It also reduces your appetite in two main ways

The claim of a favourable benefit-risk profile seems to be a bit of a judgment call, theres not much more weight loss and not many more other health benefits than with semaglutide 2.4mg and the adverse events, particularly the Dysaesthesia cluster experienced by more than 22% of the 7.2mg group, seem concerning to me